
Thursday, June 19, 2025 4:29:54 PM
As of June 19, 2025, there is no news about a Two Hands Corporation (TWOH) merger. However, there is news related to significant corporate developments that have led to speculation about potential future mergers or acquisitions. Here's a summary of recent events:
Recent Corporate Developments:
Change of Control: Emil Assentato acquired 3,000,000,000 shares of TWOH on March 31, 2025, converting outstanding convertible promissory notes. This transaction resulted in Emil Assentato now controlling 54.85% of Two Hands Corp's outstanding common shares. This qualifies as a change of control of the company.
Shareholder Meeting: A special shareholder meeting was held on March 31, 2025. At this meeting:
Shareholders approved the 3 billion share issuance to Emil Assentato.
Shareholders authorized the board of directors to implement a company name change.
Shareholders rejected a proposed 1:20,000 share consolidation.
Inactive Issuer Status: As a result of the change of control transaction and the company's intention to exit its legacy business and pursue new business opportunities, TWOH has been designated by the Canadian Securities Exchange (CSE) as an inactive issuer. This status will remain until the legacy business is resumed or a new business is initiated.
Speculation about Future Mergers/Acquisitions: Some social media posts suggest that Emil Assentato, who is now the CEO and majority shareholder of TWOH, has a history of taking companies public through SPAC mergers. This has led to speculation that he may use the TWOH shell to bring a Nasdaq-sized business or businesses public in a future merger or acquisition.
So in summation while there is no official news about a TWOH merger, the recent change of control and the company's stated intention to pursue new business opportunities have fueled speculation about a potential future reverse merger or acquisition. Investors should monitor news from the company and regulatory filings for further updates
Recent TWOH News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2025 09:13:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2025 04:14:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/02/2025 08:43:22 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/14/2025 08:58:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2025 07:32:06 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2025 12:35:31 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/14/2025 06:44:17 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/14/2025 06:43:35 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/28/2025 11:12:00 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/24/2025 01:19:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2025 04:13:35 PM
- Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 01/10/2025 04:09:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/30/2024 09:12:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/18/2024 10:18:48 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2024 09:03:41 PM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM